Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

PDAC: early-phase trial registry

6 of 7 indexed PDAC trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count

PDAC: 7 US clinical trials tracked, 6 recruiting.

PDAC is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Revolution Medicines, running 4 of these trials.

Enrollment posture brief

Registry condition pdac

OPEN 6 | RECR 86% | LATE 2 | EARLY 4 | RANK #2497 | SPON 4

Volume-matched condition peers

Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)

PDAC (this)86%ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near PDAC

PDAC lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for PDAC on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. PDAC is recruiting above its size-band peers.

    6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates PDAC research.

    Revolution Medicines accounts for 4 of 7 trials (57.1%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical PDAC enrolment sits around 574 participants.

    Median target enrolment is 574 among the 7 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.

  4. PDAC research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 32

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 3 2

Top Sponsors

Revolution Medicines 4 trials
Tango Therapeutics 1 trials
Dana-Farber Cancer Institute 1 trials
Mayo Clinic 1 trials

Named interventions

Most-linked intervention names on PDAC records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

RMC-6236 Drug
3 trials
cetuximab Drug
2 trials
daraxonrasib Drug
2 trials
Liposomal irinotecan Drug
1 trials
mFOLFIRINOX regimen Drug
1 trials
mFOLFOX6 regimen Drug
1 trials
Bio-specimen Collection: Pancreatic Juice Other
1 trials
Bio-specimen Collection: Blood Other
1 trials

US sites by state

Facility locations filed on PDAC trials. A trial with sites in several states counts in each.

Minnesota 4 trials
Massachusetts 4 trials
Virginia 3 trials
Florida 3 trials
Colorado 3 trials
Arizona 3 trials
Texas 2 trials
New York 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this PDAC page

7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This PDAC condition card totals 7 registered trials; most-linked intervention RMC-6236; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.